---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044424"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:56:26.158939+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Intellia appoints Michael P. Dube as principal accounting officer

## Summary
- Michael P. Dube, 46, appointed as principal accounting officer; currently VP and Chief Accounting Officer.
- Dube joined Intellia in September 2023; previously Global Corporate Controller at Abiomed (2012-2023).
- Dube is a CPA with 10 years at Deloitte & Touche in audit and assurance.

## SEC filing metadata
- accession: 0000950170-24-044424
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024044424/0000950170-24-044424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024044424/ntla-20240410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044424
- JSON: https://secwatch.observer/filing/0000950170-24-044424.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044424.txt

## Key facts
- Executive change
  Michael P. Dube was appointed as principal accounting officer at Intellia Therapeutics, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: On April 10, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) appointed Michael P. Dube, 46, as principal accounting officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017024044424/0000950170-24-044424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.